BrainStorm Cell Therapeutics Inc. (BCLI): Earnings per share for the last twelve months
Can Brainstorm Cell (BCLI) management adapt its R&D strategy following regulatory disputes? The answer lies in the development of the NurOwn platform and Phase 3 clinical trials for ALS aimed at accelerated FDA approval. However, geopolitics and sanctions are hindering biomaterial logistics, as evidenced by the company's revenue per employee, where the value remains at -2.01.
Analytical breakdowns and data insights for company Brainstorm Cell Therapeutics Inc. (BCLI)
- stock price and consensus target price:
- stock exchange capitalization data:
- shareholders' equity book value data:
- debt burden and liquidity indicators:
Debt to Equity Brainstorm Cell|BCLI - Long-Term Liabilities to Capital|Short-Term Debt to Equity Brainstorm Cell Therapeutics, Inc.|BCLI - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Brainstorm Cell Therapeutics Inc.|BCLI - Company Long-Term Liabilities|Company Current Liabilities BrainStorm Cell Therapeutics|Quick Ratio brainstorm-cell.com
- earnings and multiples data:
BCLI - Net Income|Projected Future Earnings Brainstorm Cell|BCLI - Market Cap to Earnings|Future Price to Earnings BrainStorm Cell Therapeutics|BCLI - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Brainstorm Cell Therapeutics Inc.|BCLI - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) BrainStorm Cell Therapeutics|BCLI - Earnings per share for the last twelve months|Quarterly EPS earnings growth brainstorm-cell.com|BCLI - Net earnings per share growth this year|Net earnings per share growth forecast for next year Brainstorm Cell
General company analysis:BCLI - Brainstorm Cell
Investing in Brainstorm Cell (BCLI) requires a rigorous analysis of the actual yield per share. This metric reflects the net profit distributed across the total issuance for the year, excluding the impact of market noise. By analyzing the earnings per share history over 12 months, an investor assesses the monetization efficiency of the NurOwn platform. For a biotech company fighting ALS, this indicator confirms the transition from costly development to capital stability. The upward trend here serves as the primary criterion for asset quality.
Competitor analysis
Biogen Inc. - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters neurocrine.com NBIX|Regencell Bioscience Holdings Limited (RGC) - Earnings per share for the last twelve months|Earnings per share for the last 12 months AXSM|Earnings per share for the last twelve months ACADIA Pharmaceuticals Inc|Xenon Corp (XENE) - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months VKTX (Viking Therapeutics)|Earnings per share for the last four quarters SUPN|Earnings per share for the last twelve months Catalyst Pharmaceuticals, Inc. CPRX|Denali (DNLI) - Net earnings per one share for the last twelve months|HRMY - Earnings per share for the last twelve months|Earnings per share for the trailing year BHVN (Biohaven Corp)|Amylyx Pharmaceuticals (AMLX) - Earnings per share for the last twelve months|Net earnings per share for the last 12 months trevitherapeutics.com|Net earnings per share for the last 12 months PRAX|AVXL: Earnings per share for the trailing year|Net earnings per share (EPS TTM) CBLL|Net earnings per share for the last 12 months Prothena Biosciences PRTA|Net earnings per share (EPS TTM) ALEC (Alector)|annexonbio.com (ANNX) - Net earnings per one share for the last twelve months|OMER - Earnings per share for the last twelve months|NGNE: Earnings per share for the last twelve months|AC Immune Corp (ACIU) - Earnings per share for the last twelve months|VYGR (Voyager Corp) - Earnings per share for the last twelve months|NMRA (Neumora Therapeutics) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months SCLX|Net earnings per share (EPS TTM) TVGN|Net earnings per share for the last 12 months alphacognition.com ACOG|Earnings per share for the last twelve months Cognition Therapeutics CGTX|Inhibikase Pharma - Earnings per share for the last twelve months|Cassava Sciences, Inc. - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Assertio Holdings, Inc. ASRT|coyatherapeutics.com (COYA) - Earnings per share for the last twelve months|Earnings per share for the last 12 months VTGN|OVID (Ovid Therapeutics Inc) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Acumen Pharmaceuticals, Inc ABOS|Net earnings per share for the last 12 months CRVO (CervoMed Inc.)|Net earnings per share (EPS TTM) alteritytherapeutics.com (ATHE)|Earnings per share for the last twelve months Clene CLNN|Earnings per share for the trailing year PEPG|JUNS - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Relmada Corp|ANVS: Net earnings per share (EPS TTM)|GRCE (Grace Therapeutics) - Earnings per share for the last twelve months|Earnings per share for the last twelve months Firefly Neuroscience|KLTO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) NRSN|Net earnings per share (EPS TTM) Reviva Pharmaceuticals, Inc. (RVPH)|Net earnings per share (EPS TTM) MTVA (MetaVia)|Net earnings per share for the last four quarters neuraxis.com (NRXS)|HSDT - Earnings per share for the last twelve months|PASG (Passage Bio, Inc.) - Earnings per share for the last 12 months|bionomics.com.au (NEUP) - Earnings per share for the last twelve months|NERV - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months ATHA|ADXN (addextherapeutics.com) - Earnings per share for the last four quarters|Earnings per share for the last twelve months Alzamend Neuro, Inc. (ALZN)|CYCN - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Protagenic Therapeutics, Inc. PTIX|Earnings per share for the trailing year KTTA|CRGT - Earnings per share for the last twelve months|avenuetx.com (ATXI) - Net earnings per share for the last 12 months|CARA (Cara Therapeutics) - Net earnings per share for the last 12 months|Chromocell Therapeutics Corp - Earnings per share for the trailing year|ELYM (Eliem Therapeutics, Inc.) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Intra-Cellular (ITCI)|Net earnings per share (EPS TTM) LBPH|MRNS - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months NKGen Biotech NKGN|NeuroBo Pharmaceuticals Inc - Earnings per share for the last twelve months|SAGE - Earnings per share for the last twelve months|SNPX: Earnings per share for the last twelve months|TRVN: Net earnings per share (EPS TTM)|VIGL (Vigil Neuroscience, Inc.) - Earnings per share for the last twelve months|WENA (Anew Medical) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Cerevel Therapeutics Inc (CERE)
